Focused On-demand Library for Phosphatidylinositol N-acetylglucosaminyltransferase subunit P

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P57054

UPID:

PIGP_HUMAN

Alternative names:

Down syndrome critical region protein 5; Down syndrome critical region protein C; Phosphatidylinositol-glycan biosynthesis class P protein

Alternative UPACC:

P57054; A0A0C4DH71; B2RB18; B2RE99; B5BU92; D3DSG7; J3KR75; Q53Y28; Q96KI1; Q9NZA6

Background:

Phosphatidylinositol N-acetylglucosaminyltransferase subunit P, also known as Down syndrome critical region protein 5, plays a crucial role in the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex. This complex is pivotal in the first step of GPI biosynthesis, facilitating the transfer of N-acetylglucosamine to phosphatidylinositol. The protein's alternative names include Down syndrome critical region protein C and Phosphatidylinositol-glycan biosynthesis class P protein.

Therapeutic significance:

The protein is implicated in Developmental and epileptic encephalopathy 55 (DEE55), a severe early-onset epilepsy with neurodevelopmental impairment. Understanding the role of Phosphatidylinositol N-acetylglucosaminyltransferase subunit P could open doors to potential therapeutic strategies for DEE55, offering hope for patients and families affected by this condition.